Published on 2 Mar 2023 on Zacks via Yahoo Finance
Investors are always looking for stocks that are poised to beat at earnings season and Sorrento Therapeutics SRNEQ may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 15 cents per share for SRNEQ, compared to a broader Zacks Consensus Estimate of a loss of 19 cents per share. This suggests that analysts have very recently bumped up their estimates for SRNEQ, giving the stock a Zacks Earnings ESP of +21.05% heading into earnings season.
Sorrento Therapeutics, Inc. Price and EPS Surprise
Sorrento Therapeutics, Inc. Price and EPS Surprise